EMA Executive Director Recruitment: Leading the Future of Medicines Regulation

By João L. Carapinha

February 23, 2026

The EMA Executive Director Recruitment procedure has opened, a pivotal role overseeing operations like medicine authorizations, safety monitoring, and EU-wide public health responses. This vacancy, with reference COM/2026/20118, reports to the EMA Management Board, managing a 2025 budget of about EUR 600 million and 900 staff in a multilingual, multicultural setting in Amsterdam. As a Temporary Agent at grade AD 14, it offers a five-year renewable mandate under Regulation (EC) No 726/2004, seeking candidates with deep management expertise.

Core Leadership Duties

The Executive Director’s responsibilities include daily administration, staff leadership, strategic planning, budget management, and stakeholder relations that support EMA’s scientific and regulatory work. Selection emphasizes proven skills in managing large teams through changes like digital transformation, upholding multidisciplinary scientific evaluations, and advancing EMA’s global mission. Required expertise covers EU medicines laws, risk analysis (assessment, management, communication), and finances, plus strengths in healthcare sciences or pharmacology from public roles engaging pharma. This enables oversight of controls and partnerships with EU bodies, Member States, and international allies. Learn more in the official recruitment notice. Applications close 19 March 2026 via the EU portal

Reference url

Recent Posts

Portugal Medicines Reserve: Strengthening Health System Resilience

By João L. Carapinha

May 4, 2026

The Portuguese Government has approved the establishment of a national and regional strategic reserve of medicines and medical devices under the Portugal Transformation, Recovery and Resilience (PTRR) plan, involving an investment of 70 million euros. This measure, announced by Prime Minister Luí...
High-Cost Drug Evaluation: Dutch Institute Reduces Assessment Times for Expensive Medications
In High-Cost Drug Evaluation, the Dutch Healthcare Institute Zorginstituut Nederland, announced that the average duration for assessing expensive hospital drug...
Amgen Financial Results: Q1 2026 Performance Breakdown
Amgen financial results for the first quarter of 2026 reveal strong performance. Revenues increased 6% to $8.6 billion. Product sales grew 4%. Volume drove most of this growth. The company generated $1.5 billion in free cash flow (Amgen, 2026). Key Performance...